Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals.
Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals.
复制标题
DOI：
10.1093/oxfimm/iqac012
复制
发表时间：
2023
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) Spike 糖蛋白的中和单克隆抗体 (mAb) 已开发用于治疗 COVID-19。虽然抗体疗法已被证明可以降低与 COVID-19 相关的住院和死亡风险，但人们对 mAb 治疗患者产生的 SARS-CoV-2 内源性免疫力以及因此对未来感染的持续易感性的了解有限。在这里，我们测量了接受 REGN-COV2 (Ronapreve) 治疗的 SARS-CoV-2 感染者的内源性抗体反应。我们发现，在大多数未接种疫苗、感染 delta 并接受 REGN-COV2 治疗的个体中，会产生内源性抗体反应，但与未治疗、感染 delta 的个体一样，中和广度有限。然而，一些在 SARS-CoV-2 感染基线时呈血清阴性的已接种疫苗的个体和一些未接种疫苗的个体在感染和 REGN-COV2 治疗后未能产生内源性免疫反应，这表明单克隆抗体治疗在某些患者群体中的重要性。
Neutralizing monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein have been developed for the treatment of COVID-19. Whilst antibody therapy has been shown to reduce the risk of COVID-19-associated hospitalization and death, there is limited understanding of the endogenous immunity to SARS-CoV-2 generated in mAb-treated patients and therefore ongoing susceptibility to future infections. Here we measure the endogenous antibody response in SARS-CoV-2-infected individuals treated with REGN-COV2 (Ronapreve). We show that in the majority of unvaccinated, delta-infected REGN-COV2-treated individuals, an endogenous antibody response is generated, but, like untreated, delta-infected individuals, there was a limited neutralization breadth. However, some vaccinated individuals who were seronegative at SARS-CoV-2 infection baseline and some unvaccinated individuals failed to produce an endogenous immune response following infection and REGN-COV2 treatment demonstrating the importance of mAb therapy in some patient populations.